MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.vaccine.2024.126175

Медицинская библиотека · Vaccine · 2024

Anti-PF4 positivity and platelet activation after Ad26.COV2·S vaccination in Brazil.

Bokel Joanna, Martins-Gonçalves Remy, Grinsztejn Eduarda, Mendes-de-Almeida Daniela P, Hoagland Brenda, Cardoso Sandra Wagner, Geraldo Kim Mattos, Coutinho Sandro Nazer, Georg Ingebourg, Oliveira Maria Helena, Dos Santos Souza Flávia, Sacramento Carolina Q, Rozini Stephane V, Vizzoni Alexandre G, Veloso Valdiléa, Bozza Patrícia T, Grinsztejn Beatriz

СтатьяПеревод пока не подготовлен

Аннотация

INTRODUCTION

The Ad26.COV2·S (Janssen/Johnson & Johnson) COVID-19 vaccine, has been rarely associated with vaccine-induced immune thrombocytopenia and thrombosis (VITT). We investigated the prevalence of anti-PF4 antibody positivity, thrombocytopenia, D-dimer elevation, plasmatic thromboinflammatory markers, and platelet functional assays following Ad26.COV2·S vaccination in Rio de Janeiro, Brazil.

METHODS

From July to September 2021, participants were assessed prior, 1, and 3 weeks post-vaccination. Platelet count and D-dimer were measured at each visit and anti-PF4 at week 3. A positive anti-PF4 prompted retrospective testing of the sample from week 0. Individuals with new thrombocytopenia or elevated D-dimer, positive anti-PF4, and 38 matched controls without laboratory abnormalities were evaluated for plasmatic p-selectin, tissue factor, and functional platelet activation assays.

RESULTS

630 individuals were included; 306 (48.57%) females, median age 28 years. Forty-two (6.67%) presented ≥1 laboratory abnormality in week 1 or 3. Five (0.79%) had thrombocytopenia, 31 (4.91%) elevated D-dimer, and 9 (1.57%) had positive anti-PF4 at week 3. Individuals with laboratory abnormalities and controls showed a slight increase in plasmatic p-selectin and tissue factor. Ten individuals with laboratory abnormalities yielded increased surface expression of p-selectin, and their ability to activate platelets in a FcγRIIa dependent manner was further evaluated. Two were partially inhibited by high concentrations of heparin and blockage of FcγRII with IV.3 antibody. Plasma obtained before vaccination produced similar results, suggesting a lack of association with vaccination.

CONCLUSIONS

Vaccination with Ad26.COV2·S vaccine led to a very low frequency of low-titer positive anti-PF4 antibodies, elevation of D-dimer, and mild thrombocytopenia, with no associated clinically relevant increase in thromboinflammatory markers and platelet activation.

Для цитирования: Bokel Joanna, Martins-Gonçalves Remy, Grinsztejn Eduarda, Mendes-de-Almeida Daniela P, Hoagland Brenda, Cardoso Sandra Wagner, Geraldo Kim Mattos, Coutinho Sandro Nazer, Georg Ingebourg, Oliveira Maria Helena, Dos Santos Souza Flávia, Sacramento Carolina Q, Rozini Stephane V, Vizzoni Alexandre G, Veloso Valdiléa, Bozza Patrícia T, Grinsztejn Beatriz. Anti-PF4 positivity and platelet activation after Ad26.COV2·S vaccination in Brazil.. Vaccine. 2024. DOI: 10.1016/j.vaccine.2024.126175.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.